Pancreatic cancer: current standards, working towards a new therapeutic approach

Olowokure, Olugbenga; Qi, Xiaoyang

doi:10.1586/14737140.2014.895937

Cited by 9 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro, the cytotoxic effect of SapC-DOPS correlated with surface PS expression on cells. Our studies have demonstrated that SapC-DOPS selectively induces apoptotic cell death in malignant pancreatic cells, whereas untransformed pancreatic ductal epithelial cells remain unaffected [13][14][15]38]. Furthermore, animals with xenograft tumors treated with SapC-DOPS showed clear survival benefits and reduced tumor size compare to untreated mice.…”

Section: Theraeutic Studies Of Sapc-dops In Cancer Cellsmentioning

confidence: 66%

SapC-DOPS – a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy

N’Guessan

Patel

2020

Cell Commun Signal

Self Cite

View full text Add to dashboard Cite

Phosphatidylserine (PS) is normally located in the inner leaflet of the membrane bilayer of healthy cells, however it is expressed at high levels on the surface of cancer cells. This has allowed for the development of selective therapeutic agents against cancer cells (without affecting healthy cells). SapC-DOPS is a PS-targeting nanovesicle which effectively targets and kills several cancer types including pancreatic, lung, brain, and pediatric tumors. Our studies have demonstrated that SapC-DOPS selectively induces apoptotic cell death in malignant and metastatic cells, whereas untransformed cells remain unaffected due to low surface PS expression. Furthermore, SapC-DOPS can be used in combination with standard therapies such as irradiation and chemotherapeutic drugs to significantly enhance the antitumor efficacy of these treatments. While the PS-targeting nanovesicles are a promising selective therapeutic option for the treatment of cancers, more preclinical studies are needed to fully understand the mechanisms leading to non-apoptotic PS expression on the surface of viable cancer cells and to determine the effectiveness of SapC-DOPS in advanced metastatic disease. In addition, the completion of clinical studies will determine therapeutic effects and drug safety in patients. A phase I clinical trial using SapC-DOPS has been completed on patients with solid tumors and has demonstrated compelling patient outcomes with a strong safety profile. Results from this study are informing future studies with SapC-DOPS.

show abstract

Section: Theraeutic Studies Of Sapc-dops In Cancer Cellsmentioning

confidence: 66%

SapC-DOPS – a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy

N’Guessan

Patel

2020

Cell Commun Signal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pancreatic cancer is one of the most lethal human cancers with a 5year survival rate of about 4-6% [1]. Early detection could significantly achieve the best clinical outcomes.…”

Section: Commentarymentioning

confidence: 99%

The Potential Diagnostic Value of Serum Cpa4 Level for Pancreatic Cancer

Sun¹,

Sun²

2018

Chemotherapy

View full text Add to dashboard Cite

“…SapC-DOPS NPs have so-called “fusogenic” activity with particles interacting with the endogenous PtdSer on cancer cells resulting in NP-cell fusion. PtdSer is highly expressed on tumor cells of certain cancers, especially high in pancreatic cancers [45], which allows for selective targeting of SapC-DOPS. SapC-DOPS contain phospholipid dioleoylphosphatidylserine (DOPS) and Saponin C (SapC), which is an 80 amino acid multifunctional glycoprotein expressed in the lysosomal membrane of all cell types.…”

Section: Therapy With Phosphatidylserine Carriersmentioning

confidence: 99%

“Eat me” imaging and therapy

Bagalkot

Deiuliis

Rajagopalan

et al. 2016

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Clearance of apoptotic debris is a vital role of the innate immune system. Drawing upon principles of apoptotic clearance, convenient delivery vehicles including intrinsic anti-inflammatory characteristics and specificity to immune cells can be engineered to aid in drug delivery. In this article, we examine the use of phosphatidylserine (PtdSer), the well-known “eat-me” signal, in nanoparticle-based therapeutics making them highly desirable “meals” for phagocytic immune cells. Use of PtdSer facilitates engulfment of nanoparticles allowing for imaging and therapy in various pathologies and may result in immunomodulation. Furthermore, we discuss the targeting of the macrophages and other cells at sites of inflammation in disease. A thorough understanding of the immunobiology of “eat-me” signals is requisite for the successful application of “eat-me”-bearing materials in biomedical applications.

show abstract

Pancreatic cancer: current standards, working towards a new therapeutic approach

Cited by 9 publications

References 20 publications

SapC-DOPS – a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy

SapC-DOPS – a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy

The Potential Diagnostic Value of Serum Cpa4 Level for Pancreatic Cancer

“Eat me” imaging and therapy

Contact Info

Product

Resources

About